Buy (150 RUB)
|Generate QR code
Open Access
Subscription or Fee Access
Drug-induced agranulocytosis – prevalence, complications, management tactics
https://doi.org/10.33667/2078-5631-2024-13-57-61
Abstract
Based on the results of a review of clinical cases and research data, the prevalence of drug-induced agranulocytosis, complications and management tactics are considered. A clinical case of agranulocytosis caused by taking nonsteroidal anti-inflammatory drugs (NSAIDs) is presented. The patient was admitted to the purulent surgical department with purulent lymphadenitis and sepsis. During the examination, agranulocytosis was revealed against the background of constant intake of NSAIDs (Aertal, Diclofenac, ibuprofen) for 3 years for joint pain. Surgical treatment was performed and antibiotic therapy was prescribed. Against the background of Filgrastim therapy, a positive dynamics of peripheral blood parameters was noted. The use of granulocyte colony stimulating factors (G-CSF) significantly reduces the severity of the disease, reduces the duration of hospitalization and mortality in patients with drug-associated agranulocytosis.
About the Authors
A. A. Pecherskikh
Pirogov Russian National Research Medical University; City Clinical Hospital No. 13
Russian Federation
Russian Federation
Pecherskikh Andrey A. - assistant at Faculty Therapy Dept of Faculty of Pediatrics Pirogov RNRMU, head of Therapeutic Dept CCH No. 13.
Moscow
B. A. Chaparyan
City Clinical Hospital No. 13
Russian Federation
Russian Federation
Chaparyan Boris A. - head of the Dept of Purulent surgery.
Moscow
N. V. Orlova
Pirogov Russian National Research Medical University
Russian Federation
Russian Federation
Orlova Natalia V. - DM Sci (habil.), professor at Dept of faculty therapy.
Moscow
T. V. Pinchuk
Pirogov Russian National Research Medical University
Russian Federation
Russian Federation
Pinchuk Tatyana V. - Associate Professor of the Dept of Faculty Therapy of the Faculty of Pediatric.
Moscow
E. S. Chernenok
Pirogov Russian National Research Medical University
Russian Federation
Russian Federation
Chernenok Ekaterina S. - resident of the Dept of Faculty Therapy of the Faculty of Pediatrics.
Moscow
N. D. Karseladze
Medical Center of the Airport of the MOW
Russian Federation
Russian Federation
Karseladze Natalia D. - PhD Med, general practitioner.
Moscow
References
1. Andrès E, Maloisel F. Idiosyncratic drug-induced agranulocytosis or acute neutropenia. Curr. Opin. Hematol. 2008 Jan; 15 (1): 15–21. https://doi.org/10.1097/MOH.0b013e3282f15fb9
2. Tesfa D, Keisu M, Palmblad J. Idiosyncratic drug-induced agranulocytosis: possible mechanisms and management. Am. J. Hematol. 2009 Jul; 84 (7): 428–34. https://doi.org/10.1002/ajh.21433
3. Diclofenac. Agranulocytosis and ecthyma gangrenosum in an elderly patient: case report. Link.springer.com. Vol. 1203. P. 18. (2008) https://doi.org/10.2165/00128415–200812030–00057
4. Lobo I, Pinto A, Ferreira M, Oliveira J, Sanches M, Reis E, Selores M. Non-pseudomonal ecthyma gangrenosum present in diclofenac-induced agranulocytosis. Eur. J. Dermatol. 2008 May-Jun;18 (3): 350–1. https://doi.org/10.1684/ejd.2008.0410
5. Jin H, Zheng R, Kim B, Yim SV. Repeated Administration of Newly Synthesized Aceclofenac Sustained Release Form Causes Agranulocytosis: Case Report of an Unforeseen Adverse Event during the Phase 1 Trial. Transl. Clin. Pharmacol. 2014 Jun; 22 (1): 11–12. https://doi.org/10.12793/tcp.2014.22.1.11
6. Kaufman DW, Kelly JP, Jurgelon JM, Anderson T, Issaragrisil S, Wiholm BE, Young NS, Leaverton P, Levy M, Shapiro S. Drugs in the aetiology of agranulocytosis and aplastic anaemia. Eur. J. Haematol. Suppl. 1996; 60: 23–30. https://doi.org/10.1111/j.1600–0609.1996.tb01641.x
7. Faich GA. Analgesic risks and pharmacoepidemiology. JAMA. 1986 Oct 3; 256 (13): 1788. PMID: 3747091.
8. Keisu M, Ekman E. Sulfasalazine associated agranulocytosis in Sweden 1972–1989. Clinical features, and estimation of its incidence. Eur. J. Clin. Pharmacol. 1992; 43 (3): 215–8. https://doi.org/10.1007/BF02333012
9. The Use of the WHO–UMC System for Standardised Case Causality Assessment, 2017. https://www.who-umc.org/media/2768/standardised-case-causality-assessment.pdf
10. Vial T, Gallant C, Choqu-Kastylevsky G, Descotes J. Treatment of drug-induced agranulocytosis with haematopoietic growth factors: a review of the clinical experience. BioDrugs. 1999 Mar; 11 (3): 185–200. https://doi.org/10.2165/00063030–199911030–00005
Review
For citations:
Pecherskikh A.A., Chaparyan B.A., Orlova N.V., Pinchuk T.V., Chernenok E.S., Karseladze N.D. Drug-induced agranulocytosis – prevalence, complications, management tactics. Medical alphabet. 2024;(13):57-61. (In Russ.) https://doi.org/10.33667/2078-5631-2024-13-57-61
Views:
589
Email this article 